Some fundamental issues with non-inferiority testing in active controlled trials

被引:145
作者
Hung, HMJ
Wang, SJ
Tsong, YL
Lawrence, J
O'Neil, RT
机构
[1] US FDA, CDER, Div Biometr 1, PKLN,OB,OPaSS, Rockville, MD 20857 USA
[2] US FDA, CDER, Div Biometr 2, OB,OPaSS, Rockville, MD 20857 USA
[3] US FDA, CDER, Quantitat Methods & Res Staff, OB,OPaSS, Rockville, MD 20857 USA
[4] US FDA, CDER, Off Biostat, OPaSS, Rockville, MD 20857 USA
关键词
efficacy; non-inferiority margin; preservation of active control effect; historical trial; alpha error;
D O I
10.1002/sim.1315
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In an active controlled non-inferiority trial without a placebo arm, it is often not entirely clear what the primary objective is. In many cases the considered goal is to demonstrate that the experimental treatment preserves at least some fraction of the effect of the active control. The active control effect is a parameter, the value of which is unknown. To test the hypothesis of effect preservation, the classical confidence interval approach requires specification of a non-inferiority margin which is a function of the unknown active control effect. When the margin is estimated, it is also not clear what is the relevant type I error of making a false assertion about preservation of the active control effect. The statistical uncertainty of the estimated margin arguably needs to be incorporated in evaluation of the type I error. In this paper we discuss these fundamental issues. We show that the classical confidence interval approach cannot attain the target type I error exactly since this error varies as the sample size or as the values of the nuisance parameters in the active controlled trial change. In contrast, the preservation tests, as proposed in literature, can attain the target type I error rate exactly, regardless of the sample size and the values of the nuisance parameters, but can do so only at the price of several strong assumptions holding that may not be directly verifiable. One assumption is the constancy condition holding whereby the effect of the active control in the historical trial populations is assumed to carry to the population of the active control trial. When this condition is violated, both the confidence interval approach and the preservation test method may be problematic. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:213 / 225
页数:13
相关论文
共 26 条
[1]  
[Anonymous], 1998, STAT PRINC CLIN TRIA
[2]   PROVING THE NULL HYPOTHESIS IN CLINICAL-TRIALS [J].
BLACKWELDER, WC .
CONTROLLED CLINICAL TRIALS, 1982, 3 (04) :345-353
[3]  
CBER/FDA, 1999, SUMM CBER CONS SEL A
[4]  
*CPMP, 1999, POINTS CONS SWITCH S
[5]  
Ebbutt AF, 1998, STAT MED, V17, P1691, DOI 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1691::AID-SIM971>3.3.CO
[6]  
2-A
[7]   Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 2: Practical issues and specific cases [J].
Ellenberg, SS ;
Temple, R .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) :464-470
[8]   Active-control trials:: How would a new agent compare with placebo?: A method illustrated clopidogrel, aspirin, and placebo [J].
Fisher, LD ;
Gent, M ;
Büller, HR .
AMERICAN HEART JOURNAL, 2001, 141 (01) :26-32
[9]  
FLEMING TR, 1987, CANCER TREAT REP, V71, P1061
[10]   Design and interpretation of equivalence trials [J].
Fleming, TR .
AMERICAN HEART JOURNAL, 2000, 139 (04) :S171-S176